Home › NDC Lookup › RxCUI directory › RxCUI 825003

168 HR granisetron 0.129 MG/HR Transdermal System — RxCUI 825003

RxNorm drug concept · Semantic clinical drug
RxCUI 825003 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI825003
Official name168 HR granisetron 0.129 MG/HR Transdermal System
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asgranisetron 3.1 MG/Day 7 Day Transdermal System; granisetron 3.1 MG/Day Weekly Transdermal Patch
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)1,022 prescriptions · 15 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Granisetron: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Granisetron is an anti-nausea medicine. It's mainly used to prevent nausea and vomiting that cancer chemotherapy or radiation therapy can cause. Depending on which product you've b...
  • The Sancuso patch delivers granisetron slowly through your skin over up to 7 days — you apply it to your upper outer arm at least 24 hours before chemotherapy starts and leave it o...
  • How does the Sancuso patch work differently from the pill or injection?
  • The most common ones are headache and constipation — these are the side effects most often reported in clinical studies. Some people also notice fever, stomach pain, or a slight ch...
📖 Read our full Granisetron guide →

🕸️ Concept Web — How 168 HR granisetron 0.129 MG/HR Transdermal Syste... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 168 HR granisetron 0.129 MG/HR Transdermal System RxCUI 825003

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Granisetron 26237
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Sancuso 807264
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Granisetron Transdermal System 1806407
    • Granisetron Topical Product 1156894
    • Granisetron Transdermal Product 1295699
    • Granisetron Transdermal System [Sancuso] 1806409
    • Sancuso Topical Product 1185407
    • Sancuso Transdermal Product 1296881
    • Transdermal System 316987
    • Topical Product 1151122
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Granisetron 0.129 MG/HR SCDC · 825002
  • Granisetron Transdermal System SCDF · 1806407
  • Granisetron Topical Product SCDG · 1156894
  • Granisetron Transdermal Product SCDG · 1295699

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 825003 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
66220-0637-31 168 h in 1 POUCH (66220-637-31) SANCUSO Cumberland Pharmaceuticals Inc. 2024-07-16
66220-0637-72 168 h in 1 POUCH (66220-637-72) SANCUSO Cumberland Pharmaceuticals Inc. 2024-07-16
Observed labelers: Cumberland Pharmaceuticals Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$688.8200
Range $688.8200–$688.8200 · middle 50% $688.8200–$688.8200 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.